Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Visit UPMC Enterprises at HLTH 2018
UPMC Enterprises is pleased to announce we are attending and sponsoring the inaugural HLTH: The Future of Healthcare conference.
Meet the Expert: Rebecca Jacobson, vice president of analytics
UPMC Enterprises’ expert in natural language processing on why the technology is essential to improving health care
How a single source of truth database is helping one health system drive analytics success
Healthcare IT News recently profiled the work done to combine Health Quests’s homegrown enterprise data …